genderrisico.nl
genderrisico.nl collects, according to its own description, peer-reviewed figures for each intervention and target group: complications, side effects, long-term outcomes and prevalence. The site is published by Stichting Genderinfo i.o. and belongs to the same network as genderinfo.nl.
The main article on this subject is Genderrisico.nl.
The emphasis is on figures from published research rather than opinion. This makes the site primarily a reference source for anyone who wants to know what is and is not known about a particular treatment.
What you can find
The main sections are medical, outcomes, research and stories. Risks are organised by category, with separate pages for each target group. The dossiers cover puberty blockers, hormone therapy, surgery, detransition, regret rates and prevalence, and discuss the reviews conducted in the United Kingdom, Sweden, France and Finland. A sources page and a series of articles round out the site.
Structure of the dossiers
The scope is apparent from the layout of the homepage. There are eight sub-dossiers on puberty blockers, nine on hormone therapy, ten on surgery, six on detransition, six on regret and outcomes, and eight on prevalence, alongside a research overview and a dossier on rapid-onset gender dysphoria. The risks are divided into seven categories, and there are four target groups and five detailed case studies. According to its own description, the site is aimed at patients, families, journalists and policymakers, and states that decisions about care belong with a doctor.
Figures and caveats
Several figures are prominently displayed on the homepage: a more than 4,400 percent increase in referrals to the British GIDS clinic between 2009 and 2016, a rate of 96 to 98 percent continuing with hormones after puberty blockers, complications in approximately 76 percent of phalloplasties, and a nineteen-fold higher suicide mortality rate after transition in Swedish research. The site says it uses peer-reviewed sources only. However, such standalone figures require context: they come from individual studies with their own populations and time periods and, on their own, say little about cause and effect. It is therefore advisable to read the original study as well. Recent articles focus mainly on developments in the United States, such as a lawsuit over reimbursement for puberty blockers and hospitals discontinuing gender-affirming care.
Why it is included in this archive
The pages under medical on this site describe the treatments in broad terms. Anyone looking for the underlying figures for each intervention can turn to genderrisico.nl. For the broader scientific discussion, see the science and debate section.